ALTIMMUNE, INC. Payments to Acquire Debt Securities, Available-for-sale
ALTIMMUNE, INC. (ALT) reported Payments to Acquire Debt Securities, Available-for-sale of $332.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-12
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $289.07M, a 6422.36% increase year-over-year.
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $43.29M, a 0.35% increase year-over-year.
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $88.55M, a 570.20% increase year-over-year.
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $149.32M, a 478.74% increase year-over-year.
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $285.45M, a 146.65% increase from fiscal 2024.
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $115.73M, a 30.58% increase from fiscal 2023.
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $88.63M, a 20.96% increase from fiscal 2022.
- ALTIMMUNE, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $73.27M, a 865.13% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 3 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 9 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $289.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $332.36M 10-Q · filed 2026-08-12 | $420.92M derived: sum of 3 quarters · filed 2026-08-12 | $570.24M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $43.29M 10-Q · filed 2026-05-13 | $131.84M derived: sum of 2 quarters · filed 2026-05-13 | $281.17M derived: sum of 3 quarters · filed 2026-05-13 | $285.60M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $88.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $237.88M derived: sum of 2 quarters · filed 2026-03-06 | $242.31M derived: sum of 3 quarters · filed 2026-08-12 | $285.45M 10-K · filed 2026-03-06 | ||||
| 2025-09-30 | $149.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $153.75M derived: sum of 2 quarters · filed 2026-08-12 | $196.89M 10-Q · filed 2025-11-06 | $210.11M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $4.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $47.57M 10-Q · filed 2026-08-12 | $60.79M derived: sum of 3 quarters · filed 2026-08-12 | $86.59M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $43.14M 10-Q · filed 2026-05-13 | $56.35M derived: sum of 2 quarters · filed 2026-05-13 | $82.16M derived: sum of 3 quarters · filed 2026-05-13 | $105.35M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $39.01M derived: sum of 2 quarters · filed 2026-03-06 | $62.21M derived: sum of 3 quarters · filed 2026-03-06 | $115.73M 10-K · filed 2026-03-06 | ||||
| 2024-09-30 | $25.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $49.00M derived: sum of 2 quarters · filed 2025-11-06 | $102.52M 10-Q · filed 2025-11-06 | $136.34M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $23.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $76.72M 10-Q · filed 2025-08-12 | $110.54M derived: sum of 3 quarters · filed 2025-08-12 | $122.12M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $53.52M 10-Q · filed 2025-05-13 | $87.35M derived: sum of 2 quarters · filed 2025-05-13 | $98.92M derived: sum of 3 quarters · filed 2025-05-13 | $120.94M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $33.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $45.40M derived: sum of 2 quarters · filed 2025-02-27 | $67.42M derived: sum of 3 quarters · filed 2025-02-27 | $88.63M 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | $11.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $33.59M derived: sum of 2 quarters · filed 2024-11-12 | $54.81M 10-Q · filed 2024-11-12 | $53.79M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $22.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $43.23M 10-Q · filed 2024-08-08 | $42.21M derived: sum of 3 quarters · filed 2024-08-08 | $67.55M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $21.21M 10-Q · filed 2024-05-09 | $20.19M derived: sum of 2 quarters · filed 2024-05-09 | $45.54M derived: sum of 3 quarters · filed 2024-05-09 | |||||
| 2022-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $24.32M derived: sum of 2 quarters · filed 2024-03-27 | $73.27M 10-K · filed 2024-03-27 | |||||
| 2022-09-30 | $25.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $74.29M 10-Q · filed 2023-11-07 | ||||||
| 2022-06-30 | $48.95M 10-Q · filed 2023-08-10 | |||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $168.00K derived: sum of 2 quarters · filed 2023-02-28 | $116.00K derived: sum of 3 quarters · filed 2023-02-28 | $7.59M 10-K · filed 2023-02-28 | $7.59M 10-K · filed 2022-03-15 | |||
| 2021-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $116.00K derived: sum of 2 quarters · filed 2022-11-10 | $7.59M 10-Q · filed 2022-11-10 | $7.59M 10-Q · filed 2021-11-09 | $61.47M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $7.42M 10-Q · filed 2022-08-11 | $7.42M 10-Q · filed 2021-08-10 | $61.30M derived: sum of 3 quarters · filed 2022-08-11 | $123.60M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $7.48M 10-Q · filed 2022-05-12 | $7.48M 10-Q · filed 2021-05-17 | $61.35M derived: sum of 2 quarters · filed 2022-05-12 | $123.65M derived: sum of 3 quarters · filed 2022-05-12 | $128.67M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $53.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $116.17M derived: sum of 2 quarters · filed 2022-03-15 | $121.19M derived: sum of 3 quarters · filed 2022-03-15 | $128.29M 10-K · filed 2022-03-15 | $128.16M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $62.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $67.31M derived: sum of 2 quarters · filed 2021-11-09 | $74.41M 10-Q · filed 2021-11-09 | $74.46M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $5.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $12.12M 10-Q · filed 2021-08-10 | $12.17M derived: sum of 3 quarters · filed 2021-08-10 | |||||
| 2020-03-31 | $7.10M 10-Q · filed 2021-05-17 | $7.15M derived: sum of 2 quarters · filed 2021-05-17 | ||||||
| 2019-12-31 | $50.31K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $28.26M 10-K · filed 2021-02-25 | ||||||
| 2019-09-30 | $28.21M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |